Mark Glickman
About Mark A. Glickman
Independent Class III director at MetaVia (MTVA), age 59, serving since May 2023. He is a member of the Audit and Compensation Committees and is designated an “audit committee financial expert,” bringing 30+ years of commercial leadership across pharma and medical devices (Esperion, Aralez, Auxilium, Otsuka, Kos/Abbott). Education: B.A. (SUNY Oswego) and M.B.A. (NYU Stern). Independence affirmed by the Board under Nasdaq/SEC standards.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| TherapeuticsMD (TXMD) | Co-Chief Executive Officer; earlier Chief Business Officer, Commercial | 2022–Jan 2023 (Co-CEO); 2021–Jan 2023 (CBO, Commercial) | Led commercial functions through asset sale to Mayne Pharma; women’s health focus |
| Esperion Therapeutics (ESPR) | Chief Commercial Officer | 2018–Dec 2020 | Built and led commercial division for first cardiovascular Rx launch |
| Aralez Pharmaceuticals | Chief Commercial Officer | Jun 2015–Mar 2018 | Built first commercial effort for previously clinical org |
| Auxilium Pharmaceuticals | EVP, Sales & Marketing | Pre-2015 (company acquired by Endo in Jan 2015) | Led commercial for portfolio of 13 products |
| Otsuka America Pharmaceuticals | Senior roles incl. SVP Sales & Marketing; VP Medical Devices | Prior roles | Expanded commercial products expertise |
| Kos Pharmaceuticals (Abbott/AbbVie) | Marketing Head; Regional Sales Director; VP Sales & Operations | Prior roles | Commercial leadership; Kos later part of Abbott/AbbVie |
External Roles
| Organization | Role | Since | Notes |
|---|---|---|---|
| BioFlorida, Inc. | President & Chief Executive Officer | Dec 2023 | Florida life sciences association |
| Otsuka Precision Health | Board Member | Mar 2024 | Director role (company not specified as public in filing) |
Board Governance
- Committee assignments: Audit Committee member (Chair: D. Gordon Strickland); Compensation Committee member (Chair: Michael Salsbury). Glickman is an audit committee financial expert; all members are independent.
- Independence: Board determined Glickman is an independent director under SEC/Nasdaq standards.
- Attendance: In 2024, no director attended fewer than 75% of Board and committee meetings; Board held 11 meetings; Audit 6; Compensation 5; Nominating/Governance 4.
- Controlled company: Dong‑A holds a majority of voting power, making MTVA a “controlled company” under Nasdaq; while exempt from some governance requirements, MTVA maintains fully independent Audit, Compensation, and Nominating committees.
Fixed Compensation
2024 actual non‑employee director compensation (as reported):
| Component | Amount (USD) |
|---|---|
| Cash fees (retainers/committee) | $55,000 |
| Stock awards (time‑vested RSUs; 5,051 units grant-date value) | $19,850 |
| Total | $74,850 |
Director compensation policy (amended May 2024, further amended Nov 2024):
| Element | Amount (USD) | Notes |
|---|---|---|
| Annual Board retainer (non‑Exec Chair) | $40,000 | Non‑employee directors |
| Non‑Executive Chair retainer | $75,000 | Chair premium |
| Committee Chair retainers | Audit $18,000; Comp $12,000; Nominating $10,000 | |
| Committee member retainers | Audit $9,000; Comp $6,000; Nominating $5,000 | |
| Initial RSU grant | $40,000 value | 50% vests at grant; remainder in two annual installments |
| Annual RSU grant | $20,000 value | Vests in full by next annual meeting/1‑yr anniversary |
| Optional retainer‑in‑RSUs | Elect to take all cash retainers as RSUs; vests quarterly | Deferral available |
Note: Based on policy, Glickman’s 2024 cash fees ($55k) match Board ($40k) + Audit member ($9k) + Compensation member ($6k).
Performance Compensation
- No performance‑based equity awards disclosed for non‑employee directors; RSUs are time‑vested.
- No stock options were granted by MTVA in 2024.
Other Directorships & Interlocks
| Company/Entity | Type | Role | Potential interlock/conflict |
|---|---|---|---|
| Otsuka Precision Health | Corporate (unspecified public/private) | Director | None disclosed with MTVA operations |
| BioFlorida | Industry association | President & CEO | None disclosed with MTVA |
No related‑party transactions involving Glickman were disclosed; Company related‑party transactions primarily involve Dong‑A as controlling stockholder in 2024–2025 financings.
Expertise & Qualifications
- Audit committee financial expert designation (SEC definition).
- Deep commercialization leadership in pharma/med‑device across multiple launches and portfolio management.
- Education: B.A. Political Science (SUNY Oswego); M.B.A. Finance & International Management (NYU Stern).
Equity Ownership
| Holder | Shares Beneficially Owned | % of Class |
|---|---|---|
| Mark A. Glickman | 8,958 | <1% |
- Beneficial ownership table includes shares issuable within 60 days from options/RSUs; for Glickman, disclosure shows 8,958 shares (no breakdown provided).
- Hedging policy: Company prohibits speculative trading and hedging transactions (e.g., short sales, options). Pledging not disclosed.
Shareholder Support (2025 Annual Meeting)
| Item | For | Withheld/Against | Abstain |
|---|---|---|---|
| Election: Mark A. Glickman (Class III) | 15,143,768 | 220,487 | — |
| Say‑on‑Pay (Advisory) | 15,128,182 | 93,199 | 142,874 |
| Reverse Stock Split Authorization | 15,160,143 | 82,570 | 121,542 |
High “For” support for Glickman suggests strong investor confidence in his Board role.
Governance Assessment
- Positives:
- Independent director with audit committee financial expertise supporting robust financial oversight.
- Strong attendance culture (no director <75%); active committee structure.
- Director pay modest and balanced (cash + time‑vested RSUs), with optional retainer‑in‑equity to enhance alignment.
- Company prohibits hedging, reducing misalignment risk.
- Watch items / potential red flags:
- Controlled company status under Nasdaq due to Dong‑A majority control; while committees are independent, overall governance is influenced by a controlling shareholder.
- Significant related‑party financing with Dong‑A (2024–2025), though none tied to Glickman personally.
- Company executed shareholder approvals for reverse stock split and warrant share issuance (capital structure/continuing listing actions indicate financing and listing pressures), not director‑specific but relevant to investor context.
Overall, no director‑specific conflicts, related‑party transactions, pledging, or pay anomalies were disclosed for Mark A. Glickman; his committee roles and financial expertise bolster board effectiveness amid controlled company dynamics.